There is a major problem from asthma in Japan due to its high prevalence, morbidity, economic cost and mortality. The striking feature of the time trends in asthma mortality in Japan is the two epidemics of asthma mortality in young people that occurred at the same time as similar epidemics in a number of other countries. These epidemics are likely to be due, at least in part, to the overuse of specific β-adrenergic receptor agonist drugs, namely isoprenaline and fenoterol. Following recent warnings by the Japanese Ministry of Health and Welfare against the use of fenoterol and the resulting reduction in fenoterol sales, together with other changes in management consistent with the recommendations of the Japanese Asthma Guidelines, the asthma mortality rate has again fallen in Japan. However, Japan still has case fatality rates that are disproportionately greater than those in other countries. One approach that can be taken to reduce the high asthma mortality rate in Japan is to develop and implement a community based asthma selfmanagement plan system of care whereby patients are provided with a practical system by which they can assess the severity of their asthma, a treatment regimen for both long-term therapy and management of a severe attack, and written guidelines provided by their medical practitioners in which assessment and treatment are integrated in a simple format. In controlled studies, this management approach has been shown not only to markedly reduce asthma mortality, in terms of reduction in hospital admissions and nocturnal wakening, but also to markedly reduce mortality from asthma. The Japanese Asthma Guidelines have advocated this approach, which is referred to as the 'asthma management zone system'. Through implementation of this system of care, together with other management initiatives, it is likely that the mortality rate from asthma will fall further over forthcoming years.
INTRODUCTION
Japan is a country with a major burden from asthma in terms of prevalence, morbidity and mortality. [1] [2] [3] Indeed, the recent International Study of Asthma and Allergies in Childhood (ISAAC) program, the first standardized international study of the prevalence of asthma symptoms in children, has identified that Japan has the highest prevalence of asthma in Asia, similar to that of many European countries 1, 2 (Table 1) . This finding was observed with both the written and video questionnaires, suggesting that the high prevalence rate is likely to be real and not due to language or cultural issues relating to the interpretation of the written questionnaire. There are also data to suggest that asthma prevalence has increased markedly in Japan over recent decades, 4 ,5 a trend that has been observed in numerous countries worldwide. 6 The prevalence of atopy, as measured by the presence of allergen-specific IgE antibodies, has also increased over recent decades in Japan 7 and internationally. 8 While it is recognized that such increases are due to changes in environmental risk factors, there is incomplete understanding of the relative importance of the numerous factors that have been implicated. Japan also experiences considerable morbidity from asthma, as indicated by the high prevalence of symptoms of severe asthma. In the ISAAC program, the proportion of teenage children in Japan reporting at least four attacks of asthma per year was 4.2%, whereas the proportion of children who had experienced current severe asthma symptoms, defined as wheezing of sufficient severity to limit speech in the past 12 months, was 2.1%. 1 These figures indicate the major burden of severe asthma in Japanese children.
In terms of mortality in the representative 5-34-year-old age group, Japan has a disproportionately high rate compared with other countries. 9 This is particularly evident when national case fatality rates are derived from the ratio of the asthma mortality rates to the prevalence rates of severe asthma for each country. This analysis shows that not only did Japan have a relatively high absolute mortality rate in the 1990s, but the proportion of severe asthmatics who died was considerably greater than other countries (Table 2) . While the mortality rate has reduced significantly in the late 1990s, the case fatality rate remains disproportionately greater than other countries.
It is possible to approach the problem of asthma mortality in Japan in a number of different ways. The approach undertaken in the present review is to first consider what is known about the trends in asthma mortality in Japan, review the circumstances associated with a fatal outcome in asthma and explore how this information can be used to develop strategies that overcome these problems of management.
TRENDS IN ASTHMA MORTALITY IN JAPAN
The striking feature of the time trends in asthma mortality in Japan is the two 'epidemics' of asthma mortality in young people that occurred at the same time as similar epidemics in a number of other countries 3, [9] [10] [11] [12] (Fig. 1) . In the 1960s, epidemics of asthma mortality occurred in at least six countries and this was attributed to the overuse of the high-dose preparation of isoprenaline, isoprenaline forte. 9, 12, 13 In Japan, the forte preparation of isoprenaline was not marketed and only a modest increase in asthma mortality was observed in the 5-34-year-old age group. 3, 10, 11 However, there was a fivefold increase in asthma mortality in the 10-14-year-old age group that paralleled the increase in total sales of β-adrenergic receptor agonist aerosols. In 1972, the Japan Ministry of Public Welfare made β-adrenergic receptor agonist aerosols prescription drugs, sales decreased and the death rate fell in both the 5-34-and 10-14-year-old age groups.
In the mid-1970s to 1980s, a second asthma mortality 'epidemic' occurred in New Zealand, linked to the use of the high-dose preparation of fenoterol. 9, 12 Although similar epidemics were not reported elsewhere, in many countries mortality increased during this period and, in some, the magnitude of the increase was substantial. In Japan, the death rate began to increase again in the 1980s, approximately doubling during this decade. 3, 11 A review of drug use by patients who died from asthma in Japan reported that fenoterol was the β-adrenergic receptor agonist used by just over one-half of patients, at a time when it had only an 18% market share. 3 While recognizing the limitations of these data, these figures yielded a relative risk of asthma death of fivefold in individuals prescribed fenoterol in Japan, an estimate consistent with those from case-control studies from New Zealand and Canada 11, 14 (Table 3 ). The time trend data in Japan also show a parallel between asthma mortality in persons aged 5-34 years since the mid-1980s and both the increase of sales of fenoterol since its introduction in 1985 and total β-adrenergic receptor agonist sales. In recognition of concerns regarding the role of fenoterol in asthma mortality, the Japanese Ministry of Health and Welfare cautioned that '. . . the use of fenoterol MDI should be avoided in children as possible'. Following this warning and the resulting reduction in fenoterol sales, together with other changes in management consistent with the recommendations of the Japanese Asthma Guidelines, [15] [16] [17] [18] the asthma mortality rate has again fallen in Japan.
Considered together with epidemiologic studies in other countries, these findings suggest that the major trends in asthma mortality in Japan over the past 40 years may well be due, at least in part, to the overuse of isoprenaline and fenoterol.
14 The findings also demonstrate the hazards of these specific β-adrenergic receptor agonist drugs, which should no longer be used in the treatment of asthma. 19 
CIRCUMSTANCES OF DEATH FROM ASTHMA
The findings from asthma mortality surveys undertaken in many countries throughout the world have consistently identified the same factors associated with management that have contributed to a fatal outcome 12, [20] [21] [22] [23] [24] (Table 4 ). The most important observation has been that, in the fatal episode, patients did not recognize or respond appropriately to the severity to their life-threatening attack of asthma, thereby leading to an inevitable delay in seeking emergency medical help. As a result, most patients who die from asthma are in extremus before they seek medical help. The reasons for the lack of recognition of the potential life-threatening nature of the attack are that the patients have commonly not been given clear written guidelines as to how to recognize a severe attack, do not have an objective method of assessment, such as peak flow monitoring, and obtain a false sense of reassurance through the frequent use of high-dose β-adrenergic receptor agonist inhaler, providing temporary but short-lived bronchodilation.
This problem has been identified in the recent Japanese asthma mortality surveys, in which the relationship between asthma death and overreliance or excessive dependence on β-adrenergic receptor agonists has been stressed. 3, 20, 25, 26 These reports also made the important point that this excessive dependence on β 2 -adrenergic receptor agonists contributed to other factors associated with a fatal outcome, such as delay in seeking emergency hospital treatment. Case reports of excessive use have been striking, with some patients using up to one canister of their β-adrenergic receptor agonist inhaler in the week preceding death, without seeking medical assistance. Furthermore, a recent case-control study identified that excessive dependence on β 2 -adrenergic receptor agonists was more than twice as common in asthmatic patients who died, than in those experiencing a near fatal attack. 27 Similar problems have been identified in terms of the long-term management of patients who die from asthma. 12, 16, [21] [22] [23] Patients and their relatives do not perceive that they are at risk of an adverse outcome, are poorly compliant with their regular therapy, often do not receive inhaled corticosteroid therapy and are infrequent attenders at their usual medical care.
These difficulties with the acute life-threatening attack and long-term management can be grouped into three main areas.
1. Inability to assess asthma severity, either in terms of chronic asthma severity or the severity of the lifethreatening attack of asthma.
2. Inadequate treatment with insufficient inhaled corticosteroid use long term, or oral steroid use in the severe attack, with the associated overreliance on β-adrenergic receptor agonist therapy.
3. Poor communication between patients and their doctors resulting in poor compliance, discontinuity of medical care and lack of written guidelines indicating what the patient should do in a severe attack.
MANAGEMENT STRATEGIES
One approach to reduce mortality is to develop management strategies that specifically address and overcome these three main groups of problems that have been identified as contributing to fatal asthma. In this way, a management strategy would need to be based on the following three principles.
1. A practical system to allow patients to assess the severity of their asthma.
2. A treatment regimen for both long-term therapy and management of the severe attack.
3. Written guidelines provided by the medical practitioner in which assessment and treatment are integrated in a simple format.
Assessment
Fundamental to the success of this strategy is the ability of patients to recognize a deterioration in asthma control. This requires the assessment of asthma severity through the educated interpretation of key symptoms and measurements of lung function. 28, 29 The development of nocturnal wakening is recognized to be a good marker of unstable asthma, whereas the poor response to the increased use of inhaled β-adrenergic receptor agonist therapy is an important marker of a severe attack requiring medical treatment. Measurements of peak flow at home, with values expressed as a percentage of normal predicted or previous best achieved recordings, are also recommended for the objective assessment of the degree of airflow obstruction. Peak flow monitoring is of particular importance in severe asthmatics, because they have been shown to have the worst perception of asthma severity. 30 
Treatment
As outlined in the Japanese Asthma Guidelines, pharmacologic therapy of asthma can be based on a step-wise approach in accordance with asthma of differing severity. It is recommended that, for most patients with persistent asthma, inhaled corticosteroid agents represent the basis of long-term therapy, with the dose varied according to asthma severity. Indeed, inhaled corticosteroids represent the only medication that has been shown to improve lung function, symptom control, quality of life, reduce the frequency and severity of attacks, and reduce the risk of asthma mortality. 31, 32 Inhaled β-adrenergic receptor agonists are the bronchodilator drugs of choice, with patients advised that they should be used 'as required' to reverse episodes of symptomatic asthma and that the increased requirement for inhaled β-adrenergic receptor agonist therapy indicates worsening asthma. 28, 29 In severe attacks, the asthmatic patient is advised to seek medical help and start oral corticosteroids according to a predetermined plan. One regimen that is now commonly used is for patients to take 30-40 mg/day prednisone until the patient returns to baseline and then take 15-20 mg/day prednisone for the same number of days. This regimen ensures that the asthmatic patient starts oral steroids early in the course of an exacerbation without being committed to an unnecessarily long course.
WRITTEN GUIDELINES
The provision of written guidelines in which selfassessment is used as the basis for changes in treatment requires the establishment of a self-management plan system of care. A number of different plans have been developed, based on the four-stage prototype outlined in Table 5 . [33] [34] [35] [36] In many respects, the first two stages can be considered to provide guidelines for the long-term management of asthma. In particular, the instructions to vary the dose of inhaled corticosteroid treatment in a step-wise manner in accordance with changes in asthma severity represents one practical method whereby the recommendations for the long-term treatment of chronic persistent asthma in adults can be implemented. The third and fourth stages provide guidelines for the treatment of severe asthma, with intensive treatment started by the patient in an attempt to prevent the development of a life-threatening attack. Thus, self-management plans represent one way in which the recommendations for acute severe and chronic persistent asthma can be brought together in a single framework.
The Japanese Asthma Guidelines have advocated this approach, which is referred to as the 'asthma management zone system'. 16 The principal difference in the Japanese system compared with the prototype outlined above is that it is based on three rather than four stages. In this way, the Japanese plan provides for the patient to recognize three stages of asthma severity, which are coded with the colors of a traffic signal light. The green zone indicates that asthma is under control and stable; if the patient's condition remains in this zone for at least 3 months, a careful step-down in long-term therapy can be considered. The yellow zone indicates caution, when the patient notices increasing asthma symptoms and the peak expiratory flow (PEF) falls to between 50 and 80% of predicted or best values. The patient is advised that this yellow zone signifies that an acute asthma attack is This plan may need to be modified with respect to the amount of detail it provides and the specific drug treatment(s) recommended at each stage. Similarly, the severity of symptoms chosen and the specific peak flow values recommended for each stage may need to be altered in accordance with physician preference and the asthmatic patient's individual needs.
in progress or that long-term asthma control is deteriorating. The treatment options in this zone include an increased use of inhaled β 2 -adrenergic receptor agonist therapy, increasing the dose of inhaled corticosteroids and/or a short course of oral steroids with medical review. The red zone signifies a medical alert, with asthma symptoms at rest, a minimal response to inhaled β-adrenergic receptor agonist and PEF values less than 50%. In this situation, the patient is advised to take high doses of their inhaled β-adrenergic receptor agonist drug while they seek emergency medical review.
EFFICACY
Despite the consensus on both the necessity and the principles underlying the development of asthma selfmanagement plans, it is only recently that their efficacy has been clearly established. The best assessment of their efficacy can be obtained from the recent systematic review of the literature, 37 which identified that selfmanagement involving provision of a written action plan led to a two-thirds reduction in hospitalizations for asthma, whereas less intensive interventions did not work. Similar findings were observed with respect to emergency hospital visits, in which the provision of a written action plan led to a 50% reduction. In studies that compared peak flow with symptom-based management plans, 37 equivalent efficacy was observed in terms of the proportion of subjects requiring hospitalization, emergency room treatment or an unscheduled visit to the doctor. There were no significant differences found in studies in which a comparison was made between those plans in which there was self-adjustment of medication by the patient according to written, predetermined criteria, or on the basis of regular review by a doctor. 37 Importantly, the use of asthma self-management plans has also been shown to markedly reduce mortality from asthma. 38 In this case-control study from Australia, the provision of a written action plan was associated with a 70% reduction in the risk of death.
ISSUES REQUIRING CLARIFICATION
Although the efficacy of the asthma self-management plan system of care has been demonstrated, there are a number of issues that have yet to be clarified, as outlined in Table 6 . While clarification will be obtained for some of these issues when specific studies are undertaken, some features, such as which components of the plan lead to the best clinical outcomes, may prove difficult to unravel, because the different features of the plans are so closely interrelated. The evidence to date suggests that it is likely that the greatest benefit from self-management plans will be obtained with the close integration of the different features of self-assessment and management.
In recommending the use of asthma self-management plans, it is also important to recognize that the requirements of individual asthmatic patients may vary considerably and that no single plan is likely to be suitable for every patient. As a result, the amount of detail plans provide, the specific drug treatment recommended at each stage and the percentage reduction in peak flow, or severity of symptoms chosen for the different therapeutic responses recommended, may need to vary, depending on the specific characteristics and needs of the asthmatic patient.
IDENTIFICATION OF PATIENTS AT RISK
Finally, it is necessary to identify those patients at high risk of a severe or life-threatening attack of asthma to ensure 270 R BEASLEY Table 6 Issues relating to the structure and implementation of asthma self-management plans that require further clarification
No. stages/levels (e.g. two-, three-vs four-stage plans) Specific peak flow percentages indicating each stage (e.g. < 60 or 70% to start oral steroids) Specific symptoms indicating each stage (e.g. nocturnal asthma, increasing β-adrenergic receptor agonist use and/or symptoms of a cold for recognizing worsening) Role of other medications (e.g. long-acting β-adrenergic receptor agonists, leukotriene antagonists, theophylline, sodium cromoglycate/nedocromil) The relationship between specific therapeutic responses and outcome (e.g. does increasing inhaled steroid dose in worsening asthma prevent further deterioration?) Which forms for different patient groups (e.g. adults vs children) Methods of implementation (e.g. doctor vs other health professionals) Intensity of implementation (e.g. how much peak flow and symptom monitoring is optimal?) that they receive special attention in terms of their ongoing medical management. A number of clinical characteristics associated with such an increased risk have been identified, relating to the presence of severe disease, characteristics of the patient or problems associated with the utilization of medical care 15, 23, [39] [40] [41] [42] (Table 7) . The most practical and useful ways in which a clinician can recognize high-risk asthmatic patients is to identify those requesting repeat prescriptions of two or more β-adrenergic receptor agonist inhalers per month, those who frequently visit their general practitioners or emergency departments with severe asthma or patients who have had a recent hospital admission. For example, a patient who has had a hospital admission for asthma in the previous year has a 16-fold increased risk of a fatal attack of asthma. 40 Among such patients, the marker that is associated with the highest risk of death is a previous admission to an intensive care unit for asthma and, in particular, the requirement for mechanical ventilation, which has a 5 year mortality rate of up to 20%. 43 A complementary approach is to identify those characteristics of individuals that put them at risk in terms of the way in which they manage their asthma or utilize medical care. These features include teenagers, those from disadvantaged socioeconomic groups and those with psychosocial problems or psychiatric disorders. 44, 45 The range of psychosocial factors that adversely affect asthma management and have been identified to be associated with near fatal or fatal asthma is extensive. One simple way of recognizing such patients is to identify those with current or recent use of major tranquillisers or sedatives, which is associated with an increased risk of a near fatal attack or death. 46, 47 
